We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immune checkpoint inhibitors in the first-line treatment of metastatic small-cell lung cancer.
- Authors
Knetki-Wróblewska, Magdalena; Kowalski, Dariusz M.; Krzakowski, Maciej
- Abstract
Small-cell lung cancer is the most aggressive form of lung cancer. Most patients are diagnosed at a late disease stage when the prognosis is poor. The treatment algorithm for small-cell lung cancer remained unchanged for years, with chemotherapy as the first-line option. However, progress has been made with the recent development of immune checkpoint inhibitors, two of which -- atezolizumab and durvalumab -- have been approved in combination with chemotherapy as first-line treatment for advanced small-cell lung cancer. This review presents detailed data concerning the efficacy and safety of atezolizumab and durvalumab from both registration trials and real-world studies, as well as the results of clinical trials of other immune checkpoints inhibitors. Finally, the issue of identifying biomarkers to predict the efficacy of immunochemotherapy is discussed.
- Subjects
IMMUNE checkpoint inhibitors; METASTASIS; LUNG cancer; SYSTEMIC family therapy; ATEZOLIZUMAB
- Publication
Oncology in Clinical Practice (2450-1654), 2022, Vol 18, Issue 2, p104
- ISSN
2450-1654
- Publication type
Article
- DOI
10.5603/OCP.2022.0011